Fresenius Medical Care AG & Co. KGaA(FMS)Earnings, Financials & Key Ratios
FMS•NYSE
$21.01
$11.74B mkt cap·10.7× P/E·Price updated May 6, 2026
AboutFresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.Show more
- Revenue$19.63B+1.5%
- EBITDA$3.27B+4.4%
- Net Income$978M+81.8%
- EPS (Diluted)1.68+82.6%
- Gross Margin25.62%+4.2%
- EBITDA Margin16.67%+2.8%
- Operating Margin9.31%+29.3%
- Net Margin4.98%+79.1%
- ROE6.51%+85.1%
- ROIC5.58%+36.6%
- Debt/Equity0.76+8.3%
FMS Key Insights
Fresenius Medical Care AG & Co. KGaA (FMS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 3.9%
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak 3Y average ROE of 4.4%
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FMS Price & Volume
Fresenius Medical Care AG & Co. KGaA (FMS) stock price & volume — 10-year historical chart
Loading chart...
FMS Growth Metrics
Fresenius Medical Care AG & Co. KGaA (FMS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.52%
5 Years1.91%
3 Years0.39%
TTM1.51%
Profit CAGR
10 Years0.38%
5 Years-3.43%
3 Years13.25%
TTM81.88%
EPS CAGR
10 Years0.68%
5 Years5.1%
3 Years43.38%
TTM259.57%
Return on Capital
10 Years8.85%
5 Years5.82%
3 Years5.58%
Last Year6.94%
FMS Recent Earnings
Fresenius Medical Care AG & Co. KGaA (FMS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026EPS
$0.53
Est $0.59
-10.2%
Revenue
$5.4B
Est $5.4B
-0.1%
Q1 2026
Feb 24, 2026EPS
$0.83
Est $0.65
+28.3%
Revenue
$6.0B
Est $5.7B
+5.3%
Q4 2025
Nov 4, 2025EPS
$0.64
Est $0.59
+8.5%
Revenue
$5.7B
Est $4.8B
+19.2%
Q3 2025
Aug 5, 2025EPS
$0.52
Est $0.50
+4.0%
Revenue
$5.6B
Est $5.0B
+13.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.53vs $0.59-10.2% | $5.4Bvs $5.4B-0.1% |
| Q1 2026 | Feb 24, 2026 | $0.83vs $0.65+28.3% | $6.0Bvs $5.7B+5.3% |
| Q4 2025 | Nov 4, 2025 | $0.64vs $0.59+8.5% | $5.7Bvs $4.8B+19.2% |
| Q3 2025 | Aug 5, 2025 | $0.52vs $0.50+4.0% | $5.6Bvs $5.0B+13.4% |
Based on last 12 quarters of dataView full earnings history →
FMS Peer Comparison
Fresenius Medical Care AG & Co. KGaA (FMS) competitors in Specialty chronic care clinics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DVA | 12.79B | 193.88 | 20.39 | 6.46% | 5.65% | 59.11% | 12.99 | |
 FXNC | 248.63M | 27.50 | 14.03 | 27.11% | 9.98% | 0.23 | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 BAX | 8.77B | 16.98 | -9.70 | 5.72% | -9.7% | -16.5% | 1.64 | |
 NVA | 31.3M | 6.53 | -3.92 | -8.88% | ||||
 NXRT | 757.54M | 29.85 | -23.69 | -3.24% | -12.67% | -10.13% | 5.18 | |
 USPH | 1.12B | 73.61 | 51.84 | 16.33% | 1.52% | 1.36% | 0.55 | |
 ACHC | 2.33B | 25.30 | -2.08 | 5.04% | -32.84% | -40.92% | 1.24 |
Compare FMS vs Peers
Fresenius Medical Care AG & Co. KGaA (FMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FMS Income Statement
Fresenius Medical Care AG & Co. KGaA (FMS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 17.78B | 16.55B | 17.48B | 17.86B | 17.62B | 19.4B | 19.45B | 19.34B | 19.63B |
| Revenue Growth % | 4.42% | -6.96% | 5.62% | 2.19% | -1.35% | 10.1% | 0.29% | -0.61% | 1.51% |
| Cost of Goods Sold | 11.78B | 11.39B | 12.08B | 12.32B | 12.85B | 14.5B | 14.53B | 14.58B | 14.6B |
| COGS % of Revenue | 66.24% | 68.85% | 69.13% | 68.99% | 72.91% | 74.77% | 74.68% | 75.4% | 74.38% |
| Gross Profit | 6B▲ 0% | 5.16B▼ 14.1% | 5.4B▲ 4.7% | 5.54B▲ 2.6% | 4.77B▼ 13.8% | 4.89B▲ 2.5% | 4.93B▲ 0.6% | 4.76B▼ 3.4% | 5.03B▲ 5.7% |
| Gross Margin % | 33.76% | 31.15% | 30.87% | 31.01% | 27.09% | 25.23% | 25.32% | 24.6% | 25.62% |
| Gross Profit Growth % | 9.25% | -14.14% | 4.67% | 2.62% | -13.8% | 2.53% | 0.64% | -3.42% | 5.73% |
| Operating Expenses | 3.71B | 3B | 3.13B | 3.23B | 2.92B | 3.38B | 3.56B | 3.36B | 3.2B |
| OpEx % of Revenue | 20.86% | 18.12% | 17.89% | 18.1% | 16.58% | 17.43% | 18.28% | 17.4% | 16.31% |
| Selling, General & Admin | 3.58B | 2.87B | 3.03B | 3.13B | 2.77B | 3.17B | 3.2B | 3.14B | 3.03B |
| SG&A % of Revenue | 20.12% | 17.31% | 17.35% | 17.55% | 15.74% | 16.34% | 16.43% | 16.25% | 15.45% |
| Research & Development | 131M | 134M | 168.03M | 193.77M | 220.78M | 228.62M | 231.97M | 183.49M | 158M |
| R&D % of Revenue | 0.74% | 0.81% | 0.96% | 1.08% | 1.25% | 1.18% | 1.19% | 0.95% | 0.8% |
| Other Operating Expenses | 0 | 0 | -73.68M | -94.52M | -72.87M | -17.06M | 127.26M | 37.95M | 11M |
| Operating Income | 2.36B▲ 0% | 3.04B▲ 28.6% | 2.27B▼ 25.3% | 2.3B▲ 1.5% | 1.85B▼ 19.6% | 1.51B▼ 18.4% | 1.37B▼ 9.4% | 1.39B▲ 1.7% | 1.83B▲ 31.2% |
| Operating Margin % | 13.28% | 18.36% | 12.99% | 12.9% | 10.51% | 7.79% | 7.04% | 7.2% | 9.31% |
| Operating Income Growth % | -5.83% | 28.62% | -25.29% | 1.54% | -19.62% | -18.38% | -9.41% | 1.68% | 31.21% |
| EBITDA | 3.1B | 3.76B | 3.86B | 4.09B | 3.48B | 3.35B | 3.12B | 3.13B | 3.27B |
| EBITDA Margin % | 17.42% | 22.74% | 22.1% | 22.9% | 19.73% | 17.27% | 16.05% | 16.21% | 16.67% |
| EBITDA Growth % | -3.5% | 21.48% | 2.65% | 5.89% | -15.02% | -3.62% | -6.83% | 0.42% | 4.38% |
| D&A (Non-Cash Add-back) | 735.48M | 724.85M | 1.59B | 1.79B | 1.62B | 1.84B | 1.75B | 1.74B | 1.44B |
| EBIT | 2.41B | 2.18B | 2.33B | 2.35B | 1.93B | 1.58B | 1.46B | 1.46B | 1.51B |
| Net Interest Income | -364.82M | -301.06M | -429.44M | -368.02M | -280.43M | -292.48M | -336.42M | -335.47M | -315M |
| Interest Income | 51.38M | 147M | 61.62M | 41.96M | 73.17M | 67.66M | 88.22M | 71.58M | 0 |
| Interest Expense | 416.2M | 448M | 491.06M | 409.98M | 353.6M | 360.14M | 424.64M | 407.04M | 0 |
| Other Income/Expense | -364.82M | -301.06M | -429.44M | -368.02M | -280.43M | -292.48M | -336.42M | -335.47M | -315M |
| Pretax Income | 2.01B▲ 0% | 2.74B▲ 36.3% | 1.84B▼ 32.8% | 1.94B▲ 5.2% | 1.57B▼ 18.8% | 1.22B▼ 22.4% | 1.03B▼ 15.3% | 1.06B▲ 2.3% | 1.51B▲ 43.1% |
| Pretax Margin % | 11.29% | 16.54% | 10.53% | 10.84% | 8.92% | 6.29% | 5.31% | 5.47% | 7.7% |
| Income Tax | 454M | 511M | 401.61M | 500.56M | 352.83M | 324.95M | 300.56M | 316.06M | 321M |
| Effective Tax Rate % | 22.61% | 18.67% | 21.83% | 25.85% | 22.45% | 26.65% | 29.1% | 29.9% | 21.23% |
| Net Income | 1.28B▲ 0% | 1.98B▲ 54.8% | 1.2B▼ 39.5% | 1.16B▼ 2.9% | 969.31M▼ 16.8% | 673.4M▼ 30.5% | 499M▼ 25.9% | 537.91M▲ 7.8% | 978M▲ 81.8% |
| Net Margin % | 7.2% | 11.98% | 6.86% | 6.52% | 5.5% | 3.47% | 2.57% | 2.78% | 4.98% |
| Net Income Growth % | 8.3% | 54.84% | -39.47% | -2.94% | -16.75% | -30.53% | -25.9% | 7.8% | 81.81% |
| Net Income (Continuing) | 1.55B | 2.23B | 1.44B | 1.44B | 1.22B | 894.33M | 732.46M | 740.87M | 1.19B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.01B | 1.14B | 1.27B | 1.12B | 1.28B | 1.46B | 1.21B | 1.19B | 0 |
| EPS (Diluted) | 2.08▲ 0% | 3.23▲ 55.3% | 1.35▼ 58.2% | 1.31▼ 3.0% | 0.83▼ 36.6% | 0.57▼ 31.3% | 0.85▲ 49.1% | 0.92▲ 8.2% | 1.68▲ 82.6% |
| EPS Growth % | 11.23% | 55.29% | -58.2% | -2.96% | -36.64% | -31.33% | 49.12% | 8.24% | 82.61% |
| EPS (Basic) | 2.09 | 3.24 | 1.35 | 1.31 | 0.83 | 0.57 | 0.85 | 0.92 | 1.68 |
| Diluted Shares Outstanding | 614.57M | 614.45M | 887.33M | 887.33M | 1.17B | 1.17B | 586.83M | 586.83M | 582.38M |
| Basic Shares Outstanding | 615.28M | 614.55M | 888.24M | 888.24M | 1.17B | 1.17B | 587.06M | 587.88M | 582.38M |
| Dividend Payout Ratio | 22.97% | 16.39% | 29.56% | 30.16% | 40.49% | 58.74% | 65.86% | 64.91% | 41.5% |
FMS Balance Sheet
Fresenius Medical Care AG & Co. KGaA (FMS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 6.37B | 7.85B | 7.17B | 7.28B | 7.97B | 8.2B | 8.7B | 7.92B | 7.9B |
| Cash & Short-Term Investments | 993.57M | 2.27B | 1.16B | 1.26B | 1.64B | 1.46B | 1.56B | 1.34B | 1.6B |
| Cash Only | 978.11M | 2.15B | 1.01B | 1.08B | 1.48B | 1.27B | 1.4B | 1.18B | 1.6B |
| Short-Term Investments | 15.46M | 119.51M | 155.55M | 179.26M | 159.18M | 187.83M | 154.37M | 163.09M | 0 |
| Accounts Receivable | 3.5B | 3.43B | 3.59B | 3.26B | 3.58B | 3.72B | 3.64B | 3.41B | 3.14B |
| Days Sales Outstanding | 71.85 | 75.67 | 75.02 | 66.7 | 74.17 | 69.99 | 68.26 | 64.35 | 58.43 |
| Inventory | 1.29B | 1.47B | 1.66B | 1.9B | 2.04B | 2.3B | 2.18B | 2.07B | 2.14B |
| Days Inventory Outstanding | 39.99 | 47 | 50.25 | 56.14 | 57.91 | 57.78 | 54.75 | 51.77 | 53.53 |
| Other Current Assets | 516.11M | 603.63M | 700.46M | 817.6M | 672.58M | 682.6M | 1.28B | 1.06B | 1.02B |
| Total Non-Current Assets | 17.65B | 18.4B | 25.77B | 24.41B | 26.4B | 27.55B | 25.23B | 25.64B | 23.1B |
| Property, Plant & Equipment | 3.49B | 3.84B | 8.52B | 8.19B | 8.55B | 8.34B | 7.45B | 7.26B | 3.01B |
| Fixed Asset Turnover | 5.09x | 4.31x | 2.05x | 2.18x | 2.06x | 2.33x | 2.61x | 2.66x | 6.51x |
| Goodwill | 12.1B | 12.21B | 14.02B | 12.96B | 14.36B | 15.79B | 14.65B | 15.17B | 0 |
| Intangible Assets | 683.06M | 681.33M | 1.43B | 1.38B | 1.46B | 1.52B | 1.36B | 1.37B | 14.83B |
| Long-Term Investments | 647.01M | 649.78M | 696.87M | 761.11M | 786.9M | 1.2B | 1.08B | 1.12B | 0 |
| Other Non-Current Assets | 725.15M | 1.02B | 1.11B | 1.13B | 1.24B | 702.46M | 681.83M | 720.02M | 5.26B |
| Total Assets | 24.03B▲ 0% | 26.24B▲ 9.2% | 32.93B▲ 25.5% | 31.69B▼ 3.8% | 34.37B▲ 8.4% | 35.75B▲ 4.0% | 33.93B▼ 5.1% | 33.57B▼ 1.1% | 31B▼ 7.6% |
| Asset Turnover | 0.74x | 0.63x | 0.53x | 0.56x | 0.51x | 0.54x | 0.57x | 0.58x | 0.63x |
| Asset Growth % | -5.8% | 9.23% | 25.5% | -3.78% | 8.45% | 4.04% | -5.1% | -1.07% | -7.64% |
| Total Current Liabilities | 5.3B | 6.27B | 7.06B | 6.06B | 7.26B | 6.47B | 6.11B | 5.66B | 6.25B |
| Accounts Payable | 737.84M | 795.05M | 835.19M | 827.39M | 857.53M | 951.58M | 885.15M | 984.32M | 738M |
| Days Payables Outstanding | 22.86 | 25.47 | 25.23 | 24.51 | 24.37 | 23.95 | 22.24 | 24.64 | 18.45 |
| Short-Term Debt | 1.65B | 2.5B | 2.62B | 1.09B | 1.92B | 1.34B | 944.6M | 577.38M | 1.61B |
| Deferred Revenue (Current) | 275.13M | 0 | 30.94M | 606.3M | 518.03M | 105.72M | 85.82M | 82.17M | 0 |
| Other Current Liabilities | 2.48B | 2.9B | 2.44B | 2.42B | 2.75B | 2.86B | 2.99B | 2.84B | 3.31B |
| Current Ratio | 1.20x | 1.25x | 1.02x | 1.20x | 1.10x | 1.27x | 1.42x | 1.40x | 1.26x |
| Quick Ratio | 0.96x | 1.02x | 0.78x | 0.89x | 0.82x | 0.91x | 1.07x | 1.03x | 0.92x |
| Cash Conversion Cycle | 88.99 | 97.19 | 100.04 | 98.34 | 107.72 | 103.83 | 100.77 | 91.48 | 93.51 |
| Total Non-Current Liabilities | 7.9B | 7.07B | 12.65B | 13.3B | 13.13B | 13.84B | 12.99B | 12.14B | 10.47B |
| Long-Term Debt | 5.79B | 5.05B | 6.46B | 6.8B | 6.65B | 7.17B | 6.96B | 6.26B | 5.69B |
| Capital Lease Obligations | 0 | 0 | 4.07B | 3.88B | 4.09B | 4B | 3.53B | 3.5B | 2.91B |
| Deferred Tax Liabilities | 467.54M | 626.52M | 739.7M | 785.89M | 868.45M | 936.48M | 750.29M | 708.89M | 0 |
| Other Non-Current Liabilities | 1.63B | 1.4B | 1.38B | 1.83B | 1.53B | 1.72B | 1.74B | 1.63B | 1.88B |
| Total Liabilities | 13.2B | 13.34B | 19.71B | 19.36B | 20.39B | 20.3B | 19.1B | 17.8B | 16.72B |
| Total Debt | 7.52B | 7.58B | 13.82B | 12.38B | 13.32B | 13.21B | 12.08B | 11B | 10.79B |
| Net Debt | 6.55B | 5.43B | 12.81B | 11.3B | 11.84B | 11.94B | 10.67B | 9.82B | 9.2B |
| Debt / Equity | 0.69x | 0.59x | 1.04x | 1.00x | 0.95x | 0.86x | 0.81x | 0.70x | 0.76x |
| Debt / EBITDA | 2.43x | 2.01x | 3.58x | 3.03x | 3.83x | 3.94x | 3.87x | 3.51x | 3.30x |
| Net Debt / EBITDA | 2.11x | 1.44x | 3.32x | 2.76x | 3.41x | 3.56x | 3.42x | 3.13x | 2.81x |
| Interest Coverage | 5.80x | 4.87x | 4.75x | 5.72x | 5.45x | 4.39x | 3.43x | 3.60x | - |
| Total Equity | 10.83B▲ 0% | 12.9B▲ 19.2% | 13.23B▲ 2.5% | 12.33B▼ 6.8% | 13.98B▲ 13.4% | 15.45B▲ 10.5% | 14.83B▼ 4.0% | 15.77B▲ 6.4% | 14.28B▼ 9.4% |
| Equity Growth % | -2.02% | 19.15% | 2.52% | -6.77% | 13.36% | 10.52% | -4.03% | 6.35% | -9.42% |
| Book Value per Share | 17.62 | 21.00 | 14.91 | 13.90 | 11.93 | 13.17 | 25.27 | 26.87 | 24.53 |
| Total Shareholders' Equity | 9.82B | 11.76B | 11.96B | 11.22B | 12.7B | 13.99B | 13.62B | 14.58B | 14.28B |
| Common Stock | 308.11M | 307.88M | 304.44M | 292.88M | 293M | 293.41M | 293.41M | 293.41M | 14.28B |
| Retained Earnings | 7.14B | 8.83B | 9.45B | 10.25B | 10.83B | 10.71B | 10.92B | 11.27B | 0 |
| Treasury Stock | -108.93M | -50.99M | -370.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.49B | -1.2B | -1.04B | -2.21B | -1.31B | -388.47M | -975.17M | -328.55M | 0 |
| Minority Interest | 1.01B | 1.14B | 1.27B | 1.12B | 1.28B | 1.46B | 1.21B | 1.19B | 0 |
FMS Cash Flow Statement
Fresenius Medical Care AG & Co. KGaA (FMS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 2.19B | 2.06B | 2.57B | 4.23B | 2.49B | 2.17B | 2.63B | 2.39B | 2.58B |
| Operating CF Margin % | 12.33% | 12.46% | 14.69% | 23.7% | 14.13% | 11.17% | 13.51% | 12.34% | 13.12% |
| Operating CF Growth % | 7.73% | -5.93% | 24.49% | 64.91% | -41.19% | -12.94% | 21.29% | -9.23% | 7.92% |
| Net Income | 1.55B | 2.23B | 1.44B | 1.44B | 1.22B | 894.33M | 732.46M | 740.87M | 939.75M |
| Depreciation & Amortization | 736M | 725M | 1.59B | 1.79B | 1.62B | 1.84B | 1.75B | 1.74B | 1.41B |
| Stock-Based Compensation | 46.81M | 10.74M | 1.99M | 0 | 0 | 0 | 32.52M | 0 | 0 |
| Deferred Taxes | -203.05M | 89.17M | 64.27M | 111.1M | 67.26M | -41.47M | -122.15M | -72.67M | -26.14M |
| Other Non-Cash Items | 156.24M | -99.92M | -518.52M | -335.14M | -322.7M | -395.77M | -327.27M | -468.62M | 123.13M |
| Working Capital Changes | -98M | -889M | -12.45M | 1.24B | -97.77M | -128.07M | 561.28M | 444.31M | 132.78M |
| Change in Receivables | -86.25M | -170.49M | -64.11M | 71.69M | -163.2M | -46.68M | -151.84M | -73.48M | -66.34M |
| Change in Inventory | -62.69M | -157.09M | -117.5M | -355.83M | -48.53M | -204.31M | -13.14M | 107.9M | -238.84M |
| Change in Payables | 518.74M | 368.39M | -164.77M | 1.37B | -363.95M | -356.79M | 108.48M | 155.59M | -14.18M |
| Cash from Investing | -991.54M | -245.04M | -3.29B | -1.33B | -1.2B | -734.73M | -544.23M | -84.94M | -666.18M |
| Capital Expenditures | -1.78B | -2.06B | -1.12B | -1.05B | -854.36M | -723.99M | -684.6M | -699.36M | -883.73M |
| CapEx % of Revenue | 10.04% | 12.45% | 6.44% | 5.89% | 4.85% | 3.73% | 3.52% | 3.62% | 4.5% |
| Acquisitions | -150.31M | 757.71M | -2.18B | -244.38M | -381.73M | 1.03M | 137M | 606.68M | 223.34M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.51B | 1.98B | 11.54M | 15.58M | 24.42M | 36.2M | 16.14M | 14.1M | 0 |
| Cash from Financing | -798.63M | -681.74M | -466.63M | -2.66B | -1.02B | -1.62B | -1.86B | -2.57B | -1.38B |
| Debt Issued (Net) | -308.33M | 160.93M | 318.55M | -1.27B | -358.9M | -1.12B | -1.19B | -1.91B | 767.1M |
| Equity Issued (Net) | -57.94M | -37.22M | -599.8M | -365.99M | 0 | 0 | 0 | 0 | -562.19M |
| Dividends Paid | -293.97M | -324.84M | -354.64M | -351.17M | -392.45M | -395.56M | -328.62M | -349.16M | -405.84M |
| Share Repurchases | -57.94M | -37.22M | -599.8M | -365.99M | 0 | 0 | 0 | 0 | -562.19M |
| Other Financing | -138.39M | -480.61M | 169.25M | -680.88M | -273.02M | -103.8M | -340.11M | -314.99M | -1.17B |
| Net Change in Cash | 269.23M▲ 0% | 1.17B▲ 333.7% | -1.14B▼ 197.5% | 73.82M▲ 106.5% | 400.12M▲ 442.0% | -207.87M▼ 152.0% | 153.44M▲ 173.8% | -241.9M▼ 257.7% | 558.32M▲ 330.8% |
| Free Cash Flow | 407M▲ 0% | 2M▼ 99.5% | 1.44B▲ 72008.0% | 3.18B▲ 120.6% | 1.64B▼ 48.6% | 1.44B▼ 11.7% | 1.94B▲ 34.7% | 1.69B▼ 13.2% | 1.7B▲ 0.5% |
| FCF Margin % | 2.29% | 0.01% | 8.25% | 17.81% | 9.28% | 7.44% | 9.99% | 8.72% | 8.64% |
| FCF Growth % | 336.78% | -99.51% | 72008% | 120.58% | -48.6% | -11.73% | 34.7% | -13.24% | 0.54% |
| FCF per Share | 0.66 | 0.00 | 1.63 | 3.59 | 1.40 | 1.23 | 3.31 | 2.87 | 2.91 |
| FCF Conversion (FCF/Net Income) | 1.71x | 1.04x | 2.14x | 3.64x | 2.57x | 3.22x | 5.27x | 4.44x | 2.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FMS Key Ratios
Fresenius Medical Care AG & Co. KGaA (FMS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 11.45% | 11.7% | 16.7% | 9.18% | 9.11% | 7.37% | 4.58% | 3.3% | 3.52% | 6.51% |
| Return on Invested Capital (ROIC) | 10.59% | 9.88% | 12.76% | 7.67% | 6.96% | 5.62% | 4.26% | 3.88% | 4.09% | 5.58% |
| Gross Margin | 32.27% | 33.76% | 31.15% | 30.87% | 31.01% | 27.09% | 25.23% | 25.32% | 24.6% | 25.62% |
| Net Margin | 6.94% | 7.2% | 11.98% | 6.86% | 6.52% | 5.5% | 3.47% | 2.57% | 2.78% | 4.98% |
| Debt / Equity | 0.74x | 0.69x | 0.59x | 1.04x | 1.00x | 0.95x | 0.86x | 0.81x | 0.70x | 0.76x |
| Interest Coverage | 5.79x | 5.80x | 4.87x | 4.75x | 5.72x | 5.45x | 4.39x | 3.43x | 3.60x | - |
| FCF Conversion | 1.72x | 1.71x | 1.04x | 2.14x | 3.64x | 2.57x | 3.22x | 5.27x | 4.44x | 2.63x |
| Revenue Growth | 11.24% | 4.42% | -6.96% | 5.62% | 2.19% | -1.35% | 10.1% | 0.29% | -0.61% | 1.51% |
FMS Frequently Asked Questions
Fresenius Medical Care AG & Co. KGaA (FMS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fresenius Medical Care AG & Co. KGaA (FMS) reported $19.63B in revenue for fiscal year 2025. This represents a 557% increase from $2.99B in 1998.
Fresenius Medical Care AG & Co. KGaA (FMS) grew revenue by 1.5% over the past year. Growth has been modest.
Yes, Fresenius Medical Care AG & Co. KGaA (FMS) is profitable, generating $978.3M in net income for fiscal year 2025 (5.0% net margin).
Dividend & Returns
Yes, Fresenius Medical Care AG & Co. KGaA (FMS) pays a dividend with a yield of 3.89%. This makes it attractive for income-focused investors.
Fresenius Medical Care AG & Co. KGaA (FMS) has a return on equity (ROE) of 6.5%. This is below average, suggesting room for improvement.
Fresenius Medical Care AG & Co. KGaA (FMS) generated $1.75B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More FMS
Fresenius Medical Care AG & Co. KGaA (FMS) financial analysis — history, returns, DCA and operating performance tools
Full FMS Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates